<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143155</url>
  </required_header>
  <id_info>
    <org_study_id>FAILCAP</org_study_id>
    <nct_id>NCT01143155</nct_id>
  </id_info>
  <brief_title>Failure and Cardiovascular Events in Community-acquired Pneumonia</brief_title>
  <acronym>FAILCAP</acronym>
  <official_title>Clinical Failure and Cardiovascular Events in Hospitalized Patients With Community-Acquired Pneumonia: The Failcap Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although failure and mortality are the most relevant outcomes in patients with
      Community-acquired Pneumonia (CAP), there is little discussion in the literature on their
      incidence and etiology. A pathophysiological approach has been recently developed and used to
      evaluate clinical failure in CAP patients. Clinical failure has been analyzed as related
      versus unrelated to CAP, considering the role that the pulmonary infection and the
      inflammatory response played in the development of this outcome. Cardiac events were
      identified as triggers of clinical failures in a significant percentage of CAP patients. The
      development of cardiovascular events have been also identified in CAP patients both on
      admission to the hospital and during hospitalization. However, data on this topic belong to
      studies evaluating only selected populations of veteran patients with CAP. Understanding
      clinical failure, as well as cardiovascular events in hospitalized patients with CAP would be
      useful in order to prevent complications during the hospitalization, to develop new treatment
      modalities and, thus, to improve outcomes.

      The objectives of this international, multicenter, observational, prospective cohort study
      will be: 1) To define incidence, timing, etiology and risk factors of clinical failure,
      related vs. unrelated to CAP, in hospitalized patients with CAP; 2) To define incidence,
      timing, and risk factors for cardiovascular events either on hospital admission or during
      hospitalization in hospitalized patients with CAP.Consecutive adult patients hospitalized for
      CAP in acute care hospitals in Europe and US will be enrolled. Daily clinical evaluations.
      Demographics, history, clinical, radiological, and antibiotic therapy data will be recorded,
      as well as serum, urinary and respiratory samples will be collected both on admission and
      during hospitalization from consenting individuals. Patients will be classified as having a
      CAP-related versus CAP-unrelated failure, according to a pathophysiological classification.
      Patients will be also classified as having or not a cardiovascular event either on admission
      or during hospitalization.The following outcomes will be measured:

      1) Incidence, timing, etiology and risk factors of clinical failure related vs. unrelated to
      CAP; 2) Incidence, timing and risk factors of cardiovascular events; 3)time to clinical
      stability, length of hospital stay, mortality at hospital discharge, and mortality at 30 and
      180 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical failure</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence rates for clinical failure will be standardized and reported. Statistically significant differences between clinical failure related vs. unrelated to CAP will be investigated. Timing of clinical failure rates for those with clinical failure related vs. unrelated to pneumonia will be standardized and reported. Etiology and risk factors of clinical failure will be investigated through linear models, in order to identify associations of factors with the outcome and possible independent groups of factors in the explanation of the outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence rates for each cardiovascular event will be reported and standardized. Etiology and risk factors of cardiovascular events will be investigated through linear models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical stability</measure>
    <time_frame>7 days</time_frame>
    <description>A patient will be considered to reach clinical stability when the following criteria will be met in a single day during hospitalization: 1) improved clinical signs (cough and shortness of breath); 2) patient will be afebrile for at least eight hours; 3) improving leukocytosis (decreased at least 10% from the previous day) or PCR or PCT 4) tolerating oral intake. Criteria for clinical stability will be evaluated daily during the first seven days of hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days from the date of admission to the date of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>30 days</time_frame>
    <description>In-hospital mortality will be considered if death by any cause will occur during hospitalization. Patients will be followed from day of admission to day 30; those who remain hospitalized for more than 30 days will be considered alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events after hospital discharge</measure>
    <time_frame>up to 180 days after hospital discharge</time_frame>
    <description>Data after hospital discharge will be collected during either a visit at clinics or a phone call performed at 30 and 180 days after the diagnosis of CAP was made. Adverse events will be considered if either death, CAP-related vs. CAP-unrelated, or re-hospitalization, CAP-related vs. CAP-unrelated, will occur within 180 days after hospital discharge. In addition, data regarding visits at general practitioner clinic, antibiotic use, cardiovascular events, discharge setting (nursing home, intermediate care facility, home) will be also collected.</description>
  </secondary_outcome>
  <enrollment type="Actual">2000</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Sputum Blood Exhaled Breath Condensate Tracheal Aspirate Pleural effusion
      Bronchoalveolar lavage Nasopharyngeal swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients admitted to any of the study centers will be screened for study
        entry. Patients with a diagnosis of community-acquired pneumonia (including those with
        health-care associated pneumonia) will be evaluated to define study entry criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1) Signed inform consent to participate in the study

        2) Criteria for community-acquired pneumonia:

          1. New pulmonary infiltrate seen on chest radiograph or CT Scan of the chest within 48
             hours after hospitalization.

             plus at least one of the following:

          2. New or increased cough with/without sputum production

          3. Fever (documented temperature -rectal or oral- &gt; 38.3 or hypothermia (documented
             temperature -rectal or oral- &lt; 36 C)

          4. Evidence of systemic inflammation (such as abnormal white blood cell count -either
             leukocytosis (&gt; 10,000/cm3) or leukopenia (&lt; 4,000/cm3) - or C-reactive protein (CRP)
             or procalcitonin (PCT) values above the local upper limit.

        3) Patients with a diagnosis of healthcare-associated pneumonia (HCAP) will be included in
        the study and a secondary analysis will performed on this subgroup of patients.

        Exclusion Criteria:

        Patients who meet at least one of the following definitions will be excluded from the
        analysis:

          1. Patient has hospital-acquired pneumonia, defined as pneumonia that develops after 48
             hours of the current hospitalization, or pneumonia that develops in a patient who had
             been discharged from the hospital within the prior 14 days of the current
             hospitalization.

          2. Patient is re-admitted with a new episode of pneumonia during the 14-day follow up
             period from the previous hospitalization.

          3. Unstable psychiatric or psychological condition rendering the subject unlikely to be
             cooperative or to complete the study requirements.

          4. Subject history that in the investigator's opinion would preclude subject compliance
             with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Blasi, M.D., PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dipartimento toraco-polmonare e cardio-circolatorio, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefano Aliberti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Respiratory Department, AO San Gerardo, University of Milan-Bicocca, Monza, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julio Ramirez, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Division of Infectious Diseases, Department of Medicine, University of Louisville, Louisville, Kentucky, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Cosentini, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Medicine Department, Fondazione IRCCS CÃ  Granda Ospedale Maggiore Policlinico, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincenzo Valenti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UO Pneumologia, IRCCS Policlinico San Donato, University of Milan, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Voza, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UO Medicina d'Urgenza, Istituto Clinico Humanitas; Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Delfino Legnani, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UO Pneumologia, Ospedale &quot;Luigi Sacco&quot;, University of Milan, Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Pesci, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Pneumologia, Azienda Ospedaliera S. Gerardo di Monza, University of Milano-Bicocca, Monza, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luca Richeldi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Respiratory Disease, University of Modena and Reggio Emilia, Modena, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daiana Stolz, M.D., MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic of Pneumology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paula Peyrani, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Infectious Diseases, University of Louisville, KY; USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento toraco-polmonare e cardio-circolatorio, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.caposite.com</url>
    <description>An International, Observational Study to Evaluate the Current Management of Hospitalized Patients with Community-Acquired Pneumonia</description>
  </link>
  <reference>
    <citation>Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001 Jun;163(7):1730-54.</citation>
    <PMID>11401897</PMID>
  </reference>
  <reference>
    <citation>Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72.</citation>
    <PMID>17278083</PMID>
  </reference>
  <reference>
    <citation>Aliberti S, Amir A, Peyrani P, Mirsaeidi M, Allen M, Moffett BK, Myers J, Shaib F, Cirino M, Bordon J, Blasi F, Ramirez JA. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest. 2008 Nov;134(5):955-962. doi: 10.1378/chest.08-0334. Epub 2008 Jun 26.</citation>
    <PMID>18583514</PMID>
  </reference>
  <reference>
    <citation>Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, Moffett B, Gordon J, Blasi F, Bordon J. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008 Jul 15;47(2):182-7. doi: 10.1086/589246.</citation>
    <PMID>18533841</PMID>
  </reference>
  <reference>
    <citation>Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007 Jul 15;45(2):158-65. Epub 2007 Jun 6.</citation>
    <PMID>17578773</PMID>
  </reference>
  <reference>
    <citation>Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008 Feb 15;46(4):550-6. doi: 10.1086/526526.</citation>
    <PMID>18194099</PMID>
  </reference>
  <reference>
    <citation>Mortensen EM, Coley CM, Singer DE, Marrie TJ, Obrosky DS, Kapoor WN, Fine MJ. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002 May 13;162(9):1059-64.</citation>
    <PMID>11996618</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2010</study_first_posted>
  <last_update_submitted>December 31, 2013</last_update_submitted>
  <last_update_submitted_qc>December 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Francesco Blasi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Community-acquired pneumonia</keyword>
  <keyword>Healthcare-associated pneumonia</keyword>
  <keyword>Failure</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

